Kiromic BioPharma, Inc. using its proprietary DIAMOND artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces favorable safety results from the histopathology evaluation of a preclinical study of the pharmacology of KB-GDT-01 administered alone and in combination with a non-biological anti-tumor therapy in mice. The histopathology report, authored by a certified veterinary pathologist, revealed no adverse microscopic findings related to the administration of Deltacel alone or as part of the combination treatment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.2 USD | -0.62% | -.--% | +267.82% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+267.82% | 4.97M | |
+11.91% | 114B | |
+11.60% | 105B | |
-4.68% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-17.47% | 16.13B | |
+2.77% | 13.75B | |
+34.58% | 11.76B |
- Stock Market
- Equities
- KRBP Stock
- News Kiromic BioPharma, Inc.
- Kiromic BioPharma, Inc. Reports Favorable Deltacel Preclinical Pharmacology Results